|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | IMbrave150研究:免疫抑制剂治疗首次取得晚期肝细胞癌一线治疗成功显示文摘【据The New England Journal of Medicine 2020年5月报道】题:阿特朱单抗联合贝伐单抗在无法手术切除的晚期肝细胞癌中的疗效(作者Finn RS等)索拉非尼和仑伐替尼是目前晚期肝细胞癌(HCC)的标准一线治疗方案,可适当提高患者总生存率,但不良反应较多。PD-1抑制剂、阿特朱单抗(PD-L1抑制剂)以及贝伐单抗在Ⅰb期和Ⅱ期临床试验中显示出良好的客观缓解率。该研究探索了阿特朱单抗联合贝伐单抗对比单药索拉非尼治疗无法手术切除的晚期HCC的疗效和安全性。 | 刘昊天 钟鉴宏 FINN RS QIN S IKEDA M | 2020 | 临床肝胆病杂志2020，36，9： | 460 |
| 2 | Dasatinib,an orally active small molecule inhibitor of both the src and abl kinases,selectively inhibits growth of basal-type/' triple-negative' breast cancer cell lines growing in vitro显示文摘 | Finn RS Dering J Ginther C | 2007 | Breast Cancer Res Treat2007，105，： | 1 |
| 3 | Dasatinib as a sin- gle agent in triple-negative breast cancer: results of an open-label phase 2 study显示文摘 | Finn RS Bengala C Ibrahim N | 2011 | Clin Cancer Res2011，17，21： | 1 |
| 4 | Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/' triple-negative' breast cancer cell lines growing in vitro显示文摘 | Finn RS Dering J Ginther C | 2007 | Breast Cancer Res Treat2007，105，3： | 1 |
| 5 | Targeting Src in breast cancer显示文摘 | Finn RS | 2008 | Ann Onco|2008，19，8： | 1 |
| 6 | Estrogen receptor, progester- one receptor, human epidermal growth factor receptor 2 ( HER2 ), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paelitaxel with lapatinib or place- bo as first-line treatment in HER2-negative or unknown metastatic breast cancer显示文摘 | Finn RS Press MF Dering J | 2009 | J Clin Oncol2009，27，24： | 1 |
| 7 | Development of molecularly targeted therapies in hepat-ocellular carcinoma:where do we go now?显示文摘 | Finn RS | 2010 | Clin Cancer Res2010，16，39： | 1 |
| 8 | Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab 显示文摘 | Finn RS Zhu AX | 2009 | Expert Rev Anticancer Ther2009，9，： | 1 |
| 9 | Emission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA- reactive drugs 显示文摘 | Pietras RJ Pegram MD Finn RS | 1998 | Oncogene1998，17，17： | 1 |
| 10 | An open-label phase Ⅱ study of first- and second-line treatment with brivanib in patients with hepatocellalar carcinoma ( HCC ) 显示文摘 | RAOUL JL FINN RS KANG YK | 2009 | J Clin Oncol2009，27，15： | 1 |
| 11 | The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor -positive, HER2 -negative, advanced breast cancer (PALOMA -1/TRIO -18) :a randomised phase 2 study 显示文摘 | Finn RS Crown JP Lang I | 2015 | Lancet Oncol2015，16，1： | 1 |
| 12 | PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor - positive human breast cancer cell lines in vitro显示文摘 | FINN RS DERING J CONKLIN D | 2009 | Breast Cancer Res2009，，5： | 1 |
| 13 | Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs显示文摘 | Pietras R J Pegram MD Finn RS | 1998 | Oncogene1998，17，8： | 1 |
| 14 | The effect of Her2/neu overexpression on cllemolherapeutie drug sensitivity in human breast and ovarian cancer eells显示文摘 | Pegram MD Finn RS Arzoo K | 1997 | Oncogene1997，15，： | 1 |
| 15 | The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of estrogen receptor-positive, HER2- negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study显示文摘 | Finn RS Crown JP Lang I | 2015 | Lancet Oncol2015，16，1： | 1 |
| 16 | The cyclin - dependenl kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first - line treatment of oestrogen receptor - positive, HER2 - negative, advaneed breast cancer (PALOMA-IrrRIO-18): a randomised phase 2 study显示文摘 | J FINN RS CROWN JP LANG I | 2015 | Lancet Oncol2015，16，1： | 1 |
| 17 | Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma显示文摘 | Park JW Finn RS Kim JS | 2011 | Clin Cancer Res2011，17，7： | 1 |
| 18 | Targeting Src in breast cancer显示文摘 | FINN RS | 2008 | Ann Oncol2008，19，8： | 1 |
| 19 | An open-label phase II study of first and second line treatment with brivanib in patient with hepatocellular carcinoma显示文摘 | RAOUL JF FINN RS KANG YK | 2009 | J Clin Oncol2009，27，15： | 1 |
| 20 | The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells 显示文摘 | Pegram MD Finn RS Arzoo K | 1997 | Oncogene1997，15，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员